Zhu Haiyan, Luo Hui, Zhang Wenwen, Shen Zhaojun, Hu Xiaoli, Zhu Xueqiong
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
Drug Des Devel Ther. 2016 Jun 7;10:1885-95. doi: 10.2147/DDDT.S106412. eCollection 2016.
Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%-20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer.
晚期或复发性宫颈癌患者预后较差，其1年生存率仅为10%-20%。化疗被认为是晚期或复发性宫颈癌患者的标准治疗方法，顺铂似乎能有效治疗该疾病。然而，可能会出现对顺铂的耐药性，从而严重影响顺铂治疗晚期或复发性宫颈癌的疗效。在本文中，我们系统回顾了近期文献，并总结了我们对宫颈癌顺铂耐药分子机制的最新认识进展。
